GLOBUS MEDICAL (NYSE:GMED) offers strong growth potential at a reasonable valuation, backed by solid financial health. A closer look at its fundamentals suggests it could be a compelling pick for growth-oriented investors.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Medical device company Globus Medical (NYSE:GMED) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP profit of $0.68 per share was 8.6% below analysts’ consensus estimates.
Globus Medical (NYSE:GMED) shows strong growth potential with solid fundamentals and a promising technical setup, making it a stock to watch for investors seeking high-growth opportunities.
Globus Medical currently trades at $75.69 per share and has shown little upside over the past six months, posting a middling return of 3.4%. However, the stock is beating the S&P 500’s 5.2% decline during that period.
Let’s dig into the relative performance of Integer Holdings (NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including STAAR Surgical (NASDAQ:STAA) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and worst performers in the medical devices & supplies - specialty industry.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 9.2%. This performance was worse than the S&P 500’s 1.8% loss.
Discover GLOBUS MEDICAL INC - A, an undervalued growth gem. NYSE:GMED is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
